Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens

Trends in Microbiology

Volumn 9, Issue 9, 2001, Pages 445-451

  Pirofski, Liise anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; FUNGUS ANTIBODY; FUNGUS VACCINE; GLUCURONOXYLOMANNAN; PEPTIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CRYPTOCOCCUS NEOFORMANS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL VACCINES; HUMANS; MOLECULAR MIMICRY; POLYSACCHARIDES; VACCINES, CONJUGATE;

FILOBASIDIELLA NEOFORMANS; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035449899     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(01)02134-5     Document Type: Review

References (69)

1. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection
2. Cryptococcosis in the era of AIDS - 100 Years after the discovery of Cryptococcus neoformans
3. Human cryptococcosis
4. Quantitative and qualitative differences in the serum antibody profiles of HIV-infected persons with and without Cryptococcus neoformans meningitis
5. Biochemistry
6. Cryptococcus neoformans: Paradigm for the role of antibody in immunity
7. Protective murine monoclonal antibodies to Cryptococcus neoformans
8. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies
9. Protection of mice against experimental cryptococcosis by an anti-Cryptococcus neoformans monoclonal antibody
10. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
11. Characterization of a murine monoclonal antibody to C. neoformans polysaccharide which is a candidate for human therapeutic studies
12. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: Synthesis, characterization, and immunogenicity
13. Protein conjugates of polysaccharide from Cryptococcus neoformans
14. Peptide mimicry of the polysaccharide capsule of Cryptococcus neoformans
15. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans
16. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection
17. T cell-independent antigens type 2
18. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide
19. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine
20. H3 gene segment usage
21. Production of protective human anti-pneumococcal antibodies by transgenic mice with human immunoglobulin loci
22. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS
23. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives
24. H3 (D12 idiotope) B cells in vivo
25. H3 expression in peripheral B cells from HIV-uninfected, but not HIV-infected individuals
26. H3 gene products: Natural ligands for HIV gp120
27. The use of licensed vaccines for active immunization of the immunocompromised host
28. Abundance of restricted fetal B cell repertoire in marrow transplant recipients
29. Immunoglobulin VH gene expression in human aging
30. Aberrant V(H) utilization in patients with established insulin dependent diabetes mellitus
31. A B cell superantigen-induced persistent 'Hole' in the V-1 repertoire
32. Highly reduced protection against Streptococcus pneumoniae pneumonia after deletion of a single heavy chain gene in mouse
33. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial
34. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogenic bone marrow transplantation
35. The 1996 Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide vaccines
36. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
37. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults
38. IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults
39. Immunoregulation by capsular components of Cryptococcus neoformans
40. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell
41. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
42. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
43. Antifungal activity of a human antiglucuronoxylomannan antibody
44. Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannan antibodies
45. Dispute slows paper on 'remarkable' vaccine
46. Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans
47. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition
48. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and non-protective antibodies
49. Searching for peptide ligands with an epitope library
50. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library
51. Discovering peptide ligands using epitope libraries
52. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody
53. Peptide mimicry of the meningococcal group C capsular polysaccharide
54. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines
55. Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help
56. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites
57. Molecular basis for the lack of mimicry of Brucella polysaccharide antigens by αβ2γ antibodies
58. Immunoglobulin M efficacy against Cryptococcus neoformans: Mechanism, dose dependence, and prozone-like effects in passive protection experiments
59. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide
60. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response
61. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity
62. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics
63. Protection against measles-virus induced encephalitis by anti-mimotope antibodies: The role of antibody affinity
64. Exploring the basis of peptide-carbohydrate crossreactivity: Evidence for discrimination by peptides between closely related anti-carbohydrate antibodies
65. A molecular basis for functional peptide mimicry of a carbohydrate antigen
66. The three dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage library: Implications for the identification of peptide mimotopes
67. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan
68. H clan and family identity predicts variable domain structure and may influence antigen binding
69. Are there two distinct research strategies for developing biologically active molecules: Rational design and empirical selection?